Table 3.
Author, Year, Country | Study design | Study period | Number | Follow-up (months) | Sample | Measured indicators | Detected method | Cut-off value | Survival analysis | Source of HR | Analytic method | NOS score |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Siegel, 2014, USA | P | 2008–2012 | 140 | 8 | Serum | AdipoQ; Leptin | RIA |
≥13.05 μg/ml vs<13.05 μg/ml; ≥7.9 ng/ml vs<7.9 ng/ml |
OS | Report | M;U | 7 |
Shen, 2016, USA | P | 2008–2014 | 135 | 84 | Plasma | AdipoQ | ELISA | ≥13.10 μg/ml vs<13.10 μg/ml | OS | Report | M | 7 |
Shin, 2014, Korea | P | 1996–2001 | 75 | 82.5 | Cytoplasmic | AdipoQ | IHC | Positive: > 0% of cells stained vs Negative: no cells stained | OS | Report | M | 6 |
Watanabe, 2011, Japan | P | 2006–2008 | 33 | 39 | Plasma | Leptin | NA | ≥5.0 ng/ml vs<5.0 ng/ml | DFS | Report | M | 7 |
Wang, 2014, Taiwan | P | 1999–2003 | 85 | NA | Cytoplasmic | AdipoQ | IHC | Low: - ~ + vs High: ++ ~ +++a | OS | SC | M | 7 |
Wang, 2006, Taiwan | P | 1994–2003 | 68 | 31.7 | Cytoplasmic | Leptin | IHC | Low: - ~ + vs High: ++ ~ +++a | OS | SC | M | 6 |
ELISA Enzyme-linked immunosorbent assay, RIA Radioimmunoassay, IHC Immunohistochemistry, NA Not available, DFS Disease-free survival, OS Overall survival, SC Survival curves, U Univariate, M Multivariate. aSemiquantitative scoring system, NOS Newcastle-Ottawa Scale